Technology area: Biotechnology & Pharmaceuticals
52 pending office actions • 27 art units • 50 examiners • 1 of 52 (2%) have an AI response strategy ready • 90 patents granted in the last 365 days
Eli Lilly and Company maintains 55 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 53 distinct examiners, showing a low concentration of cases per examiner. While the examiner pool is large, these individuals are situated within 28 distinct art units, suggesting that multiple examiners are often working within the same technical groups. The 28 distinct art units involved indicate a diverse range of technical subject matter within the broader Biotechnology & Pharmaceuticals field.
The busiest examiner, ISMAIL, REHANA, is currently handling 2 pending office actions. This figure represents a small portion of the 55 total actions, reinforcing the observation that the portfolio is spread across the examining corps. With 53 distinct examiners involved, the company faces a wide array of individual perspectives and negotiation styles. Practitioners must coordinate across these 28 units, which is a smaller number than the 53 examiners, implying some consistency in unit-level policies despite the variety of individual examiners. This environment requires a strategy that balances individual examiner preferences with the broader procedural trends observed within the 28 distinct art units.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 5 (10%) |
| §103 only | 9 (17%) |
| §102 only | 1 (2%) |
| §112 only | 7 (13%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 10 (19%) |
| Multi-statute (no §101) | 15 (29%) |
| No statute on record | 2 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 2 | 76.2% | +34.8% |
| BALLARD, KIMBERLY | 2 | 53.6% | +49.5% |
| PARIHAR, PRADHUMAN | 1 | 56.8% | +20.7% |
| BALAJ, ANTHONY MICHAEL | 1 | 31.2% | +29.2% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| SHELDEN, BION A | 1 | 22.1% | +20.1% |
| GILLIGAN, CHRISTOPHER L | 1 | 57.5% | +40.3% |
| ALAWADI, SARAH | 1 | 37.7% | +38.3% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 31d overdue |
| 18323674 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | NOTTINGHAM, KYLE GREGORY | 22d overdue |
| 18713758 | SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS | HEIN, DEVIN C | 33d |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | MOU, LIYUAN | 34d |
| 18565484 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | O DELL, DAVID K | 61d |
| 18950247 | TECHNIQUES FOR PROCESSING WIRELESSLY BROADCAST PACKETS FROM A MEDICAL DEVICE WITH DOSE-RELATED DATA | GILLIGAN, CHRISTOPHER L | 63d |
| 19477673 | METHODS AND SYSTEMS FOR MANAGING DIABETES | BALAJ, ANTHONY MICHAEL | — |
| 19348544 | PEPTIDES FOR INCRETIN SYNTHESIS | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 31d overdue |
| 18950247 | TECHNIQUES FOR PROCESSING WIRELESSLY BROADCAST PACKETS FROM A MEDICAL DEVICE WITH DOSE-RELATED DATA | GILLIGAN, CHRISTOPHER L | 63d |
| 19397018 | METHODS OF CLEANING CHROMATOGRAPHY MATRICES | PARIHAR, PRADHUMAN | — |
| 19477673 | METHODS AND SYSTEMS FOR MANAGING DIABETES | BALAJ, ANTHONY MICHAEL | — |
| 19348544 | PEPTIDES FOR INCRETIN SYNTHESIS | D' AMBROSIO, THEA | — |
| 18864287 | GLP1 TABLET COMPOSITIONS | ALAWADI, SARAH | — |
| 18933587 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ISMAIL, REHANA | — |
| 18857347 | FGFR2 INHIBITOR COMPOUNDS | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 3783 | 8 |
| 1675 | 6 |
| 1654 | 4 |
| 1658 | 3 |
| 1641 | 3 |
| 1625 | 2 |
| 1626 | 2 |
| 1674 | 2 |
| 1621 | 2 |
| 1628 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19397018 | METHODS OF CLEANING CHROMATOGRAPHY MATRICES | PARIHAR, PRADHUMAN | 1714 | §103 | Non-Final OA | — | Pending | Nov 21, 2025 |
| 19477673 | METHODS AND SYSTEMS FOR MANAGING DIABETES | BALAJ, ANTHONY MICHAEL | 3682 | §101§103 | Non-Final OA | — | Pending | Oct 22, 2025 |
| 19348544 | PEPTIDES FOR INCRETIN SYNTHESIS | D' AMBROSIO, THEA | 1654 | §102§103 | Non-Final OA | — | Pending | Oct 02, 2025 |
| 19104909 | INFUSION SITE FAILURE DETECTION | SHELDEN, BION A | 3685 | §101§112 | Final Rejection | 31d overdue | AI Ready | Feb 19, 2025 |
| 18950247 | TECHNIQUES FOR PROCESSING WIRELESSLY BROADCAST PACKETS FROM A MEDICAL DEVICE WITH DOSE-RELATED DATA | GILLIGAN, CHRISTOPHER L | 3683 | §101§112 | Final Rejection | 63d | Pending | Nov 18, 2024 |
| 18864287 | GLP1 TABLET COMPOSITIONS | ALAWADI, SARAH | 1619 | §112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18933587 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ISMAIL, REHANA | 1625 | §112DP | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18857347 | FGFR2 INHIBITOR COMPOUNDS | FETTEROLF, BRANDON J | — | §112 | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18828945 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | COUGHLIN, MATTHEW P | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18826275 | AT2R ANTAGONISTS AND USES THEREOF | ISMAIL, REHANA | 1625 | DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18745159 | MEDICATION DELIVERY DEVICE WITH GEAR SET DOSAGE SYSTEM | MENDEZ, MANUEL A | 3783 | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18713758 | SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS | HEIN, DEVIN C | 3686 | §101 | Final Rejection | 33d | Pending | May 28, 2024 |
| 18612180 | METHODS OF PRODUCING FC-CONTAINING PROTEINS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18595872 | CONNECTED INJECTION DEVICES WITH STATUS SENSING SYSTEMS | VARGAS, ANNA ELIZABETH | 3783 | §102 | Non-Final OA | 70d | Pending | Mar 05, 2024 |
| 18686475 | SYSTEMS AND METHODS FOR SENSING DEFECATION EVENTS | OKONAK, ELIZABETH LOUISE | 3792 | §103 | Final Rejection | 27d | Pending | Feb 26, 2024 |
| 18684025 | THERAPEUTIC AGENT DELIVERY DEVICE | PATEL, SHEFALI DILIP | 3783 | §102§103§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18428443 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | WITHERSPOON, SIKARL A | 1692 | Other | Final Rejection | — | Pending | Jan 31, 2024 |
| 18428102 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18409277 | THERAPEUTIC USES OF DULAGLUTIDE | CHANDRA, GYAN | 1674 | §102§103DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18571825 | COMPOSITIONS OF EXTENDED RELEASE COATINGS AND METHODS FOR APPLYING EXTENDED RELEASE COATINGS | RODRIGUEZ, CRIS LOIREN | 3783 | §103 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18571397 | METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA | HAMA, JOANNE | 1647 | §103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18531856 | GITR ANTAGONISTS AND METHODS OF USING THE SAME | ESSEX, LAURA ANN | 1675 | DP | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18565484 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | O DELL, DAVID K | 1621 | §102§103Other | Non-Final OA | 61d | Pending | Nov 29, 2023 |
| 18501175 | AHR AGONISTS | COPPINS, JANET L | 1628 | §112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18549693 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | ELENISTE, PIERRE PAUL | 1622 | §103§112DP | Final Rejection | 60d overdue | Pending | Sep 08, 2023 |
| 18549803 | ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF | WEIDNER, ADAM M | 1675 | §102§103§112Other | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18547460 | SELF-ASPIRATING SYRINGE SYSTEMS, CARTRIDGES, AND METHODS | AHMED, TASNIM M | 3783 | §102§103 | Final Rejection | — | Pending | Aug 22, 2023 |
| 18546483 | GIP/GLP1 DUAL AGONIST THERAPEUTIC METHODS | HELLMAN, KRISTINA M | 1654 | §103§112DP | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18366061 | TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES | TAYLOR, LIA ELAN | 1641 | §101§112DP | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18344134 | KRAS G12C INHIBITOR DOSING REGIMENS | FERGUSON, JALISA HOLMES | 1626 | §103§112Other | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18258698 | RNA THERAPEUTICS AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Jun 21, 2023 |
| 18258462 | Therapeutic Peptide Formulations | KOMATSU, LI N | 1658 | §103§112DP | Non-Final OA | 56d | Pending | Jun 20, 2023 |
| 18258018 | HUB FOR REUSABLE DRUG-DELIVERY DEVICE | ACKUN, JACOB K | 3783 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18266717 | METHODS OF TREATING DIABETES | YANG, TIAN | 1674 | §112 | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18323674 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | NOTTINGHAM, KYLE GREGORY | 1621 | §102§103§112 | Final Rejection | 22d overdue | Pending | May 25, 2023 |
| 18297099 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | NICKOL, GARY B | 1643 | Other | Non-Final OA | — | Pending | Apr 07, 2023 |
| 18247198 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN ANTIBODY PURIFICATION PROCESSES AND ANTIBODY COMPOSITIONS HAVING REDUCED HOST CELL PROTEIN CONTENT | SZPERKA, MICHAEL EDWARD | 1641 | §103§112DP | Non-Final OA | — | Pending | Mar 29, 2023 |
| 18041898 | METHODS AND APPARATUS FOR DISPLAYING GLUCOSE DATA | HANEY, JONATHAN MICHAEL | 3791 | §103 | Non-Final OA | — | Pending | Feb 16, 2023 |
| 17787015 | ENDOTOXIN DETECTION | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 118d overdue | Pending | Feb 06, 2023 |
| 18040282 | MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM | SCHMIDT, EMILY LOUISE | 3783 | §103 | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | MOU, LIYUAN | 1628 | §103§112Other | Final Rejection | 34d | Pending | Jan 12, 2023 |
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | SAOUD, CHRISTINE J | 1645 | §103Other | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17905580 | SUBCUTANEOUS ABSORPTION AND BIOAVAILABILITY OF ANTIBODIES | GAO, ASHLEY HARTMAN | 1678 | §101§103§112 | Final Rejection | — | Pending | Sep 02, 2022 |
| 17905520 | MULTISPECIFIC BINDING PROTEINS AND METHODS OF DEVELOPING THE SAME | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | 42d overdue | Pending | Sep 02, 2022 |
| 17883072 | Anti-CGRP Antibody Formulation | WANG, CHANG YU | 1675 | §112 | Non-Final OA | 14d | Pending | Aug 08, 2022 |
| 17795797 | THERAPEUTIC USES OF DULAGLUTIDE | HA, JULIE | 1654 | §103§112 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17711099 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | BALLARD, KIMBERLY | 1675 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2022 |
| 17554713 | Anti-CGRP Antibody Formulation | BORGEEST, CHRISTINA M | 1675 | §103Other | Non-Final OA | 4d overdue | Pending | Dec 17, 2021 |
| 17535059 | COMPOUNDS AND METHODS TARGETING HUMAN TAU | BALLARD, KIMBERLY | 1675 | §112 | Non-Final OA | — | Pending | Nov 24, 2021 |
| 17507414 | METHODS OF TREATING CROHN'S DISEASE | GUSTILO, ESTELLA M | 1646 | §103§112Other | Non-Final OA | — | Pending | Oct 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEli Lilly and Company has 52 pending office actions as of October 2026, spread across 27 art units and 50 examiners.
Rehana Ismail has the most, with 2 of Eli Lilly and Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
